Processing

Please wait...

Settings

Settings

Goto Application

1. CA2163344 - HUMANISED ANTIBODIES

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]
CLAIMS
1. A recombinant antibody molecule having specificity for antigenic determinants dependent on the DRĪ± chain.
2. A recombinant antibody molecule according to Claim 1 having specificity for the epitope recognised by the murine monoclonal antibody L243.
3. A recombinant antibody molecule according to Claim 1 or Claim 2 which is a humanised CDR-grafted or chimeric antibody molecule.
4. A humanised antibody molecule according to Claim 3 wherein at least one of the complementarity determining regions (CDRs) of the variable domain is derived from the mouse monoclonal antibody
L243 and the remaining immunoglobulin-derived parts of the humanised antibody molecule are derived from a human immunoglobulin or an analogue thereof.
5. A CDR-grafted humanised antibody heavy chain according to Claim 4 having a variable region domain comprising human acceptor framework and donor antigen binding regions wherein the framework comprises donor residues at at least one or more of positions 27, 67, 69, 71, 72 and 75.
6. A CDR-grafted humanised antibody heavy chain according to Claim 5 comprising donor residues at positions 27, 67, 69, 71, 72 and 75.
7. A CDR-grafted humanised antibody heavy chain having a variable region domain comprising human acceptor frameworks derived from human group consensus sequence 1 and L243 donor antigen binding regions wherein the framework comprises L243 donor residues at one of more of positions 27, 67, 69, 71, 72 and 75.
8. A CDR-grafted humanised antibody light chain according to Claim 4 having a variable region domain comprising human acceptor framework and donor antigen binding regions wherein the framework comprises donor residues at at least one or more of positions 45, 49, 70 and 71.
9. A CDR-grafted humanised antibody light chain according to Claim 7 comprising donor residues at positions 45, 49, 70 and 71.
10. A CDR-grafted humanised antibody light chain having a variable region domain comprising acceptor frameworks derived from human group consensus sequence 1 and L243 donor antigen binding regions wherein the framework comprises L243 donor residues at one or more of positions 45, 49,70 and 71.
11. A DNA sequence which codes for a CDR-grafted heavy chain according to any one of Claims 5 or 6 and/or a CDR-grafted light chain according to any one of Claims 8 or 9.
12. A cloning or expression vector containing a DNA sequence according to Claim 11.
13. A host cell transformed with a cloning or expression vector according to Claim 12.
14. A process for the production of a CDR-grafted antibody having specificity for the epitope recognised by the murine monoclonal antibody L243 comprising expressing a DNA sequence according to Claim 11 or 12 in a transformed host cell.
15. A process for producing a recombinant or humanised antibody having specificity for the epitope recognised by the murine monoclonal antibody L243 comprising. a) producing in an expression vector an operon having a DNA sequence which encodes an antibody heavy or light chain comprising a variable domain wherein at least one of the CDRs of
the variable domain is derived from the L243 MAb and the remaining immunoglobulin-derived parts of the antibody chain are derived from a human immunoglobulin b) producing in an expression vector an operon having a DNA sequence which encodes a complementary antibody light or heavy chain comprising a variable domain wherein at least one of the
CDRs of the variable domain is derived from the MAb L243 and the remaining immunoglobulin-derived parts of the antibody chain are derived from a human immunoglobulin c) transfecting a host cell with both operons; and d) culturing the transfected cell line to produce the humanised antibody molecule.
16. A therapeutic, pharmaceutical or diagnostic composition comprising a recombinant antibody molecule according to Claim 1 or Claim 2 in combination with a pharmaceutically acceptable carrier, diluent or excipient.
17. A process for the preparation of a therapeutic, pharmaceutical or diagnostic composition comprising admixing a recombinant antibody molecule according to Claim 1 or Claim 2 with a pharmaceutically acceptable excipient diluent or carrier.
18. A method of therapy or diagnosis comprising administering an effective amount of a recombinant antibody molecule according to
Claim 1 or Claim 2 to a human or animal subject.